Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3D MedicinesHKSE:01244 +3.33%49 Gross Margin % is 91.89% as of Dec. 2025, which is 0% below its 10-year median of 92.27. GuruFocus rates HKSE:01244 with a GF Score™ of 49/100 and a GF Value™ of HK$3.15 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 735 Biotechnology companies, 3D Medicines ranks better than 87.48% on this metric.
3D Medicines (HKSE:01244) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
3D Medicines had a gross margin of 91.89% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
3D Medicines Gross Margin % Related Terms
3D Medicines Gross Margin % Historical Data
* Premium members only.
The historical data trend for 3D Medicines's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01244 vs VRTX, REGN, RVMD: Gross Margin % Comparison
For the Biotechnology subindustry, 3D Medicines's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Medicines Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Medicines's Gross Margin % distribution charts can be found below:
* The bar in red indicates where 3D Medicines's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
3D Medicines (HKSE:01244) has a Gross Margin % of 91.89% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on 3D Medicines and its competitors. This is near median its historical median of 92.27. Over the past decade, 3D Medicines' Gross Margin % has ranged from 91.79 to 92.90. According to the industry distribution chart, 3D Medicines ranks #92 out of 735 companies in the Biotechnology industry, placing it in the top 12.5%.
Is 3D Medicines' Gross Margin % too high?
3D Medicines' current Gross Margin % of 91.89% is near median its 10-year median of 92.27. Over the past 10 years, this metric has ranged from a low of 91.79 to a high of 92.90. The Biotechnology industry median Gross Margin % is 60.91. 3D Medicines' value of 91.89% is 50.9% above this industry median. Based on the distribution chart, 3D Medicines ranks #92 out of 735 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3D Medicines has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does 3D Medicines' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Medicines ranks #92 out of 735 companies for Gross Margin %. This places 3D Medicines in the top 13% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. 3D Medicines' value of 91.89% is 50.9% above this benchmark. Historically, 3D Medicines' own Gross Margin % has ranged from 91.79 to 92.90 over the past decade. While the company's 10-year median is 92.27 vs. the industry median of 60.91, 3D Medicines has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 735 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3D Medicines's current Gross Margin % of 91.89% is 50.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on 3D Medicines and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3D Medicines's current Gross Margin % is 91.89%, which is near median its own 10-year median of 92.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Medicines stock overvalued right now?
Based on GuruFocus' analysis, 3D Medicines (HKSE:01244) is currently considered Possible Value Trap. The stock's GF Value™ is HK$3.15, compared to a current price of HK$2.02 — trading 36% below its estimated fair value. The current Gross Margin % is 91.89%, which is near median its 10-year median of 92.27 and 50.9% above the Biotechnology industry median of 60.91. 3D Medicines' overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For 3D Medicines (HKSE:01244), the current Gross Margin % is 91.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Medicines (HKSE:01244) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued.
The current stock price of HK$2.02 is trading 36% below its estimated GF Value™ of HK$3.15.
GuruFocus considers 3D Medicines to be Possible Value Trap.
Key valuation signals for HKSE:01244:
Gross Margin %: 91.89% (near median its 10-year median of 92.27)
GF Value™: HK$3.15 vs. price of HK$2.02 (36% below fair value)
Industry Position: 50.9% above the Biotechnology median (#92 of 735)
No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
49GF Score
Get the complete analysis for HKSE:01244
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01244 has been successfully added to your 
